… Lung cancer is the most common cause of cancer deaths. … However, with the understanding
of lung cancer biology, and … non–small-cell lung cancer (NSCLC). Epidermal growth factor …

… , already registered for the treatment of advanced breast cancer and currently under
investigation in non-small-cell lung cancer [20]. In lung cancer, growth inhibition with trastuzumab …

… non–small cell lung cancer and other types of solid tumors. A number of newer inhibitors are
… of activity or mechanisms of receptor inhibition. These include monoclonal antibodies, such …

… Several strategies for inhibition of EGFR, including tyrosine kinase inhibition, have been
developed for treatment of human cancers, including lung cancer. EGFR is frequently …

… advanced non–small-cell lung cancer have taken place in the past … Epidermal growth factor
receptor (EGFR) inhibitors cause … Studies of EGFR inhibitors in combination chemotherapy in …

… Thus, combined HDAC inhibitor and gefitinib treatment represents a novel pharmacologic
strategy for overcoming resistance to EGFR inhibitors in patients with lung cancer. (Cancer …

… of the inhibitor. Crucially, … inhibition of FGFR kinase activity, while improving response
to classic therapeutic agents, could be efficient as a monotherapy for a subset of lung cancer …

… -cell lung cancer (NSCLC) is the leading cause of cancer-related … In particular, the epidermal
growth-factor receptor superfamily … Several selective inhibitors of this family of receptors are …

… of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights
for new lung cancer therapies, as well as for the broader field of targeted cancer therapies. …

… of lung cancers but not in breast cancers.Trastuzumab, an MoAb directed against the HER-2
protein, inhibits the growth of HER2-amplified/HER-2–overexpressing breast cancer cells in …